Time-dependent changes in skeletal response to teriparatide: escalating vs. constant dose teriparatide (PTH 1-34) in osteoporotic women.

Yu EW, Neer RM, Lee H, Wyland JJ, de la Paz AV, Davis MC, Okazaki M, Finkelstein JS

Bone24 Nov 2010Cited by 17 (Europe PMC)

PMID21111078PMCIDPMC3073572DOI10.1016/j.bone.2010.11.012PepBankPUB-21111078

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with low bone density, bone markers differed significantly between escalating and constant teriparatide doses.
In plain wordsIn women with low bone density, bone markers differed significantly between increasing and constant teriparatide doses.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedBone marker trajectories
Study
n = 52
Comparator
Constant teriparatide 30 μg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily for 6 months, then 30 μg daily for 6 months, then 40 μg daily for 6 months · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
All bone markers differed significantly between the two treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We randomized 52 postmenopausal women with low spine and/or hip bone mineral density (BMD) to either a constant or an escalating subcutaneous teriparatide dose (30 μg daily for 18months or 20 μg daily for 6 months, then 30 μg daily for 6 months, and then 40 μg daily for 6 months).
Summary · context
Serum procollagen I N-terminal propeptide, osteocalcin, and C-terminal telopeptide of type I collagen were assessed frequently.
Report a problemFND-2111107801
02HumanRandomized controlled trialEfficacy outcome
In women with low bone density, bone markers remained stable or increased with escalating teriparatide but declined with constant dosing during the final six months.
In plain wordsIn women with low bone density, bone markers stayed stable or increased with increasing doses but decreased with constant doses during the final six months.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedBone markers in final six months
Study
n = 52
Comparator
Constant teriparatide 30 μg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily for 6 months, then 30 μg daily for 6 months, then 40 μg daily for 6 months · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
During the final six months, bone markers declined in the constant dose group but remained stable or increased in the escalating dose group (all markers, p<0.017).
2 context sentences(design, population, supporting numbers)
Summary · context
We randomized 52 postmenopausal women with low spine and/or hip bone mineral density (BMD) to either a constant or an escalating subcutaneous teriparatide dose (30 μg daily for 18months or 20 μg daily for 6 months, then 30 μg daily for 6 months, and then 40 μg daily for 6 months).
Summary · context
Serum procollagen I N-terminal propeptide, osteocalcin, and C-terminal telopeptide of type I collagen were assessed frequently.
Report a problemFND-2111107802
03HumanRandomized controlled trialEfficacy outcome
In women with low bone density, mean bone marker area under the curve did not differ between escalating and constant teriparatide doses.
In plain wordsIn women with low bone density, overall bone marker exposure did not differ between increasing and constant teriparatide doses.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBone marker area under the curve
Study
n = 52
Comparator
Constant teriparatide 30 μg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily for 6 months, then 30 μg daily for 6 months, then 40 μg daily for 6 months · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
Nonetheless, mean area under the curve did not differ between treatments for any bone marker, and BMD increases were equivalent in both treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We randomized 52 postmenopausal women with low spine and/or hip bone mineral density (BMD) to either a constant or an escalating subcutaneous teriparatide dose (30 μg daily for 18months or 20 μg daily for 6 months, then 30 μg daily for 6 months, and then 40 μg daily for 6 months).
Summary · context
Serum procollagen I N-terminal propeptide, osteocalcin, and C-terminal telopeptide of type I collagen were assessed frequently.
Report a problemFND-2111107803
04HumanRandomized controlled trialEfficacy outcome
In osteoporotic women, BMD increases were equivalent with escalating and constant teriparatide doses.
In plain wordsIn women with osteoporosis, bone density increases were equivalent with increasing and constant teriparatide doses.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBMD increases
Study
n = 52
Comparator
Constant teriparatide 30 μg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily for 6 months, then 30 μg daily for 6 months, then 40 μg daily for 6 months · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
Nonetheless, mean area under the curve did not differ between treatments for any bone marker, and BMD increases were equivalent in both treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We randomized 52 postmenopausal women with low spine and/or hip bone mineral density (BMD) to either a constant or an escalating subcutaneous teriparatide dose (30 μg daily for 18months or 20 μg daily for 6 months, then 30 μg daily for 6 months, and then 40 μg daily for 6 months).
Summary · context
Serum procollagen I N-terminal propeptide, osteocalcin, and C-terminal telopeptide of type I collagen were assessed frequently.
Report a problemFND-2111107804
05HumanNon-randomized trialMechanism
In women receiving constant-dose teriparatide, acute urinary cyclic AMP response did not change over 18 months.
In plain wordsIn women receiving constant-dose teriparatide, the acute urinary cyclic AMP response did not change over 18 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeAcute urinary cyclic AMP response
Study
n: not reported in source
Comparator
Earlier response during treatment
Outcome group
Receptor activity and mechanism · Kidney and urinary
Studied dose
30 μg daily · subcutaneous · 18 monthsAs given in this study (human).
Source sentences
Summary
Acute renal response to teriparatide, as assessed by urinary cyclic AMP, did not change over 18 months of teriparatide administration.
3 context sentences(design, population, supporting numbers)
Summary · context
Acute changes in urinary cyclic AMP in response to teriparatide were examined in a subset of women in the constant dose group.
Summary · context
We randomized 52 postmenopausal women with low spine and/or hip bone mineral density (BMD) to either a constant or an escalating subcutaneous teriparatide dose (30 μg daily for 18months or 20 μg daily for 6 months, then 30 μg daily for 6 months, and then 40 μg daily for 6 months).
Summary · context
Serum procollagen I N-terminal propeptide, osteocalcin, and C-terminal telopeptide of type I collagen were assessed frequently.
Report a problemFND-2111107805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00086619

Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women

Massachusetts General Hospitaln = 80May 2004 to Dec 2009

Postmenopausal Osteoporosis · Osteoporosis

Trial page ClinicalTrials.govUpdated 30 Oct 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.